Jean-Charles Soria

Jean-Charles Soria has been a leading clinical investigator in designing combination strategies to prevent cancer drug resistance, demonstrating through landmark clinical trials that upfront combinations of targeted agents addressing anticipated resistance mechanisms produce superior outcomes compared to sequential monotherapy approaches. His EGFR-mutant NSCLC trials showed that combining osimertinib with other agents at first-line prevents the emergence of resistance that inevitably occurs with monotherapy. He established clinical trial frameworks for evaluating resistance prevention strategies and defined the concept of anticipatory combination therapy. His clinical research has shifted the paradigm from treating resistance after it emerges to preventing it.